CClinicalTrials.gg
CompletedNCT06348849Updated Jan 30, 2025

The Desensitising Effect of Nanosilver Fluoride in Molar-Incisor Hypomineralisation

A Phase 2/3 interventional study of Low-level laser therapy and Nanosilver fluoride in Molar Incisor Hypomineralization and Hypersensitivity, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 7 Years to 10 Years. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by Alexandria University · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
7 Years to 10 Years
Sex
All
01

Study summary

The aim of the current study is to assess the desensitising effect of nanosilver fluoride on first permanent molars (FPMs) in patients with MIH in comparison to low-level laser therapy.

02

Conditions studied

  • Molar Incisor Hypomineralization
  • Hypersensitivity

Keywords

  • Nanosilver fluoride
  • Low-level laser therapy
  • Desensitising
  • Molar-incisor hypomineralisation
  • First permanent molars
  • Pediatric
  • Clinical trial
  • Nanosilver
  • LLLT
03

In context

Molar Hypomineralization

121 studies on the registry are indexed under Molar Hypomineralization; 41 are open to participants now.

This study's enrollment of 120 is above the median of 52 across 94 interventional studies indexed under Molar Hypomineralization.

Browse Molar Hypomineralization studies →

Lead sponsor

Alexandria University is the lead sponsor of 570 studies on the registry; 126 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The presence of at least one hypersensitive first permanent molar in MIH patient (using the Schiff Cold Air Sensitivity Scale (SCASS)).
  • Completion of an informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Hypomineralised molars resulting from other medical conditions, such as enamel malformations associated with syndromes, dental fluorosis, enamel hypoplasia, amelogenesis imperfecta, and dental caries.
  • The presence of active tooth decay or defective restorations in the tooth under examination which can confound the aetiology of hypersensitivity with pulpitis.
  • The presence of pulpal symptoms.
  • Having undergone any professional desensitising treatment in the previous 6 months.
  • Having used a desensitising paste other than habitual toothpaste in the previous 3 months.
  • Use of anti-inflammatory drugs or analgesics at the time of recruitment.
  • Allergy or sensitivity to silver or any of the materials included in the study.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    Low-level laser therapy

    These hypersensitive molars with MIH will receive low-level laser therapy.

    Device: Low-level laser therapy

  • Experimental
    Nanosilver fluoride

    These hypersensitive molars with MIH will receive nanosilver fluoride treatment.

    Drug: Nanosilver fluoride

Interventions

  • DeviceLow-level laser therapy

    Wavelength 980nm (SmartM, Lasotronix, Poland)

  • DrugNanosilver fluoride

    Optimized synthesis of Nanosilver Fluoride

06

What researchers measure

Primary outcomes

  1. Desensitising effect in hypersensitive MIH molars

    This will be performed using Schiff Cold Air Sensitivity Scale (SCASS). The SCASS will be used to assess subject response to this stimulus (0=no response to the stimulus; 1=no response to the stimulus, patient considers stimulus to be painful; 2= response to stimulus, patient moves from the stimulus; 3= response to the stimulus, patient moves from the stimulus and requests immediate discontinuation of the stimulus)

    Time frame: 1 month

Secondary outcomes

  1. Change in the plaque index scores

    This will be assessed using the modified plaque index (PlI) of Silness and Löe. Each tooth will be scored from 0 (lowest) to 3 (highest) according to the amount of plaque accumulation. The total score will be determined by calculating the average score of the examined teeth.

    Time frame: 1 month

  2. Change in children's frequency of toothbrushing

    The frequency of toothbrushing will be assessed using a question adapted from the World Health Organization (WHO) questionnaire- child version. The parent will be asked about the number of times his/her child brushes their teeth (never - several times a month - once a week - several times a week - once daily - twice or more daily)

    Time frame: 1 month

07

Study locations

1 site
  • Faculty of Dentistry, Alexandria University
    Alexandria, 21521, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06348849
Lead sponsor
Alexandria University
Responsible party
Nouran Nabil (Instructor, Alexandria University) — Principal investigator
First posted
Apr 5, 2024
Start date
Apr 1, 2024
Primary completion
Jun 1, 2024
Completion
Aug 1, 2024
Last update
Jan 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion